ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Boehringer Ingelheim, AstraZeneca and Bristol-Myers Squibb side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

Boehringer Ingelheim×AstraZeneca×Bristol-Myers Squibb×Three at a time for now; Pro will compare up to ten.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

Boehringer IngelheimAstraZenecaBristol-Myers Squibb
studies on the registry2,3054,1972,184
open to participants now61298155
phase 3 studies under way2820082
reach primary completion within a year4516867
programswith a study of their own in two years45+21 named only119+5 named only57+9 named only

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseBoehringer IngelheimAstraZenecaBristol-Myers Squibb
Phase 1

Boehringer Ingelheim: 18 of its 45 programs at phase 1

  1. BI 3821001phase 1
  2. BI 3000202_low dosephase 1
  3. BI 3776528phase 1
  4. BI 3810944phase 1
  5. BI 3814916phase 1

and 13 more — sign in to see them all

40%

AstraZeneca: 25 of its 119 programs at phase 1

  1. AZD4954phase 1
  2. AZD1613phase 1
  3. AZD1390phase 1
  4. Actinium Ac 225-DOTA-Anti-STEAP2 Monoclonal Antibody AZD2284phase 1
  5. ALXN2230phase 1

and 20 more — sign in to see them all

21%

Bristol-Myers Squibb: 17 of its 57 programs at phase 1

  1. BMS-986454phase 1
  2. orevandrodegphase 1
  3. Actinium Ac 225 SSTR2-targeted Agent RYZ401phase 1
  4. BMS-985521phase 1
  5. BMS-986485phase 1

and 12 more — sign in to see them all

30%
Phase 2

Boehringer Ingelheim: 15 of its 45 programs at phase 2

  1. BI 3034701phase 2
  2. Anti-SIRPa Monoclonal Antibody BI 770371phase 2
  3. BI 1584862phase 2
  4. BI 1815368phase 2
  5. BI 3000202phase 2

and 10 more — sign in to see them all

33%

AstraZeneca: 47 of its 119 programs at phase 2

  1. AZD9550phase 2
  2. zadavotide guraxetanphase 2
  3. palacaparibphase 2
  4. Berzanoflastphase 2
  5. AZD7798phase 2

and 42 more — sign in to see them all

39%

Bristol-Myers Squibb: 17 of its 57 programs at phase 2

  1. irafamdastatphase 2
  2. moponetugphase 2
  3. delocamtenphase 2
  4. imzokitugphase 2
  5. Cyclophosphamidephase 2

and 12 more — sign in to see them all

30%
Phase 3

Boehringer Ingelheim: 9 of its 45 programs at phase 3

  1. obrixtamigphase 3
  2. survodutidephase 3
  3. nerandomilastphase 3
  4. verducatibphase 3
  5. zongertinibphase 3

and 4 more — sign in to see them all

20%

AstraZeneca: 28 of its 119 programs at phase 3

  1. rilvegostomigphase 3
  2. datopotamab deruxtecanphase 3
  3. tremelimumabphase 3
  4. volrustomigphase 3
  5. Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012Fphase 3

and 23 more — sign in to see them all

24%

Bristol-Myers Squibb: 16 of its 57 programs at phase 3

  1. navlimetostatphase 3
  2. pumitamigphase 3
  3. adagrasibphase 3
  4. golcadomidephase 3
  5. zolacabtagene autoleucelphase 3

and 11 more — sign in to see them all

28%
Approved, new studies

Boehringer Ingelheim: 3 of its 45 programs at approved, new studies

  1. empagliflozinapproved, new study
  2. Tenecteplaseapproved, new study
  3. Pramipexoleapproved, new study
7%

AstraZeneca: 19 of its 119 programs at approved, new studies

  1. durvalumabapproved, new study
  2. acalabrutinibapproved, new study
  3. trastuzumab deruxtecanapproved, new study
  4. osimertinibapproved, new study
  5. anifrolumabapproved, new study

and 14 more — sign in to see them all

16%

Bristol-Myers Squibb: 7 of its 57 programs at approved, new studies

  1. xanomelineapproved, new study
  2. trospiumapproved, new study
  3. deucravacitinibapproved, new study
  4. Nivolumabapproved, new study
  5. trospium chlorideapproved, new study

and 2 more — sign in to see them all

12%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Boehringer Ingelheim20 readouts · 3 phase 3·

Boehringer Ingelheim, Dec ’26: 8 programs whose next study reaches primary completion, 1 in phase 3

  1. survodutidephase 3 · Dec 8 · NCT07768813
  2. zongertinibphase 3 · Dec 10 · NCT06151574
  3. empagliflozinapproved, new study · Dec 11 · NCT07845630
  4. vicadrostatphase 3 · Dec 11 · NCT07845630
  5. verducatibphase 3 · Dec 14 · NCT07781631

and 3 more — sign in to see them all

·

Boehringer Ingelheim, Feb ’27: 1 program whose next study reaches primary completion

  1. BI 3776528phase 1 · Feb 3 · NCT06745297

Boehringer Ingelheim, Mar ’27: 4 programs whose next study reaches primary completion

  1. BI 764524phase 2 · Mar 5 · NCT06321302
  2. ezabenlimabphase 3 · Mar 8 · NCT05846516
  3. BI 765423phase 2 · Mar 11 · NCT07036523
  4. BI 3812465phase 2 · Mar 23 · NCT07553429

Boehringer Ingelheim, Apr ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. nerandomilastphase 3 · Apr 15 · NCT06806592
·

Boehringer Ingelheim, Jun ’27: 1 program whose next study reaches primary completion

  1. BI 3821001phase 1 · Jun 22 · NCT07908004

Boehringer Ingelheim, Jul ’27: 2 programs whose next study reaches primary completion

  1. BI 3814916phase 1 · Jul 12 · NCT07486115
  2. BI 3032950phase 2 · Jul 30 · NCT06636656

Boehringer Ingelheim, Aug ’27: 2 programs whose next study reaches primary completion

  1. BI 3802876phase 2 · Aug 5 · NCT07325526
  2. Anti-SIRPa Monoclonal Antibody BI 770371phase 2 · Aug 31 · NCT06806852
·

Boehringer Ingelheim, Oct ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. Tenecteplaseapproved, new study · Oct 2 · NCT07361302
AstraZeneca60 readouts · 16 phase 3

AstraZeneca, Nov ’26: 4 programs whose next study reaches primary completion

  1. Autologous dnTGF-BRII-armored Anti-STEAP2 CAR T-cells AZD0754phase 2 · Nov 24 · NCT06267729
  2. STEAP2-targeting Radioconjugate AZD2287phase 2 · Nov 24 · NCT06267729
  3. durvalumabapproved, new study · Nov 30 · NCT07081633
  4. tremelimumabphase 3 · Nov 30 · NCT07081633

AstraZeneca, Dec ’26: 7 programs whose next study reaches primary completion, 2 in phase 3

  1. eculizumabapproved, new study · Dec 7 · NCT06724809
  2. AZD3974phase 1 · Dec 8 · NCT07290283
  3. baxdrostatphase 3 · Dec 10 · NCT07222917
  4. dapagliflozinapproved, new study · Dec 10 · NCT07222917
  5. benralizumabapproved, new study · Dec 23 · NCT05692180

and 2 more — sign in to see them all

AstraZeneca, Jan ’27: 13 programs whose next study reaches primary completion, 6 in phase 3

  1. laroprovstatphase 3 · Jan 4 · NCT07000136
  2. anifrolumabapproved, new study · Jan 6 · NCT05925803
  3. monalizumabphase 3 · Jan 8 · NCT05221840
  4. oleclumabphase 3 · Jan 8 · NCT05221840
  5. datopotamab deruxtecanphase 3 · Jan 11 · NCT06417814

and 8 more — sign in to see them all

AstraZeneca, Feb ’27: 7 programs whose next study reaches primary completion, 3 in phase 3

  1. Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012Fphase 3 · Feb 1 · NCT06530849
  2. trastuzumab deruxtecanapproved, new study · Feb 10 · NCT06271837
  3. Berzanoflastphase 2 · Feb 11 · NCT07215702
  4. acalabrutinibapproved, new study · Feb 15 · NCT02972840
  5. zibotentanphase 3 · Feb 18 · NCT06087835

and 2 more — sign in to see them all

AstraZeneca, Mar ’27: 4 programs whose next study reaches primary completion

  1. AZD7760phase 2 · Mar 8 · NCT06749457
  2. AZD4954phase 1 · Mar 17 · NCT07812077
  3. AZD0543phase 1 · Mar 24 · NCT07824622
  4. Anti-Claudin 18.2 Antibody-drug Conjugate AZD4360phase 2 · Mar 31 · NCT06921928

AstraZeneca, Apr ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. AZD1043phase 1 · Apr 9 · NCT07511205
  2. camizestrantphase 3 · Apr 20 · NCT05774951
  3. ombetoxabartphase 2 · Apr 20 · NCT07285213

AstraZeneca, May ’27: 5 programs whose next study reaches primary completion, 2 in phase 3

  1. rilvegostomigphase 3 · May 4 · NCT04379596
  2. Anti-CD20/Anti-CD3/Anti-CD8 Trispecific Antibody AZD5492phase 2 · May 5 · NCT06916806
  3. AZD1613phase 1 · May 22 · NCT07228364
  4. Budesonideapproved, new study · May 31 · NCT07073950
  5. formoterolapproved, new study · May 31 · NCT07073950

AstraZeneca, Jun ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. tozorakimabphase 3 · Jun 7 · NCT06932263
  2. ravulizumabapproved, new study · Jun 25 · NCT07308574
  3. Anti-GPC3 T Cell-engaging Antibody AZD9793phase 2 · Jun 30 · NCT06795022

AstraZeneca, Jul ’27: 3 programs whose next study reaches primary completion

  1. ALXN1920phase 2 · Jul 2 · NCT07157787
  2. AZD2389phase 2 · Jul 7 · NCT07610837
  3. SC rilvegostomig + rHuphase 1 · Jul 19 · NCT07161414

AstraZeneca, Aug ’27: 4 programs whose next study reaches primary completion

  1. ALXN2230phase 1 · Aug 9 · NCT07352423
  2. AZD0240phase 1 · Aug 30 · NCT06218914
  3. SC durvalumab + rHuphase 1 · Aug 30 · NCT07391670
  4. AZD6793phase 2 · Aug 31 · NCT07082738

AstraZeneca, Sep ’27: 2 programs whose next study reaches primary completion

  1. palacaparibphase 2 · Sep 29 · NCT05123482
  2. puxitatug samrotecanphase 3 · Sep 29 · NCT05123482

AstraZeneca, Oct ’27: 5 programs whose next study reaches primary completion, 1 in phase 3

  1. opemalirsenphase 2 · Oct 4 · NCT06824987
  2. cevolisiranphase 2 · Oct 11 · NCT06744647
  3. tarperprumigphase 2 · Oct 11 · NCT07160608
  4. torvutatug samrotecanphase 3 · Oct 15 · NCT07402915
  5. sodium zirconium cyclosilicateapproved, new study · Oct 30 · NCT07944378
Bristol-Myers Squibb22 readouts · 7 phase 3

Bristol-Myers Squibb, Nov ’26: 2 programs whose next study reaches primary completion, 2 in phase 3

  1. trospiumapproved, new study · Nov 24 · NCT06585787
  2. xanomelineapproved, new study · Nov 24 · NCT06585787

Bristol-Myers Squibb, Dec ’26: 7 programs whose next study reaches primary completion, 1 in phase 3

  1. actinium AC-225 dotatatephase 3 · Dec 0 · NCT05477576
  2. navlimetostatphase 3 · Dec 5 · NCT07777133
  3. delocamtenphase 2 · Dec 14 · NCT06122779
  4. golcadomidephase 3 · Dec 14 · NCT07763418
  5. moponetugphase 2 · Dec 17 · NCT06268886

and 2 more — sign in to see them all

Bristol-Myers Squibb, Jan ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. mezigdomidephase 3 · Jan 10 · NCT05519085

Bristol-Myers Squibb, Feb ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. Actinium Ac 225 SSTR2-targeted Agent RYZ401phase 1 · Feb 0 · NCT07165132
  2. Nivolumabapproved, new study · Feb 5 · NCT06946797
  3. repotrectinibphase 3 · Feb 16 · NCT06140836

Bristol-Myers Squibb, Mar ’27: 1 program whose next study reaches primary completion

  1. trospium chlorideapproved, new study · Mar 29 · NCT07063342
·

Bristol-Myers Squibb, May ’27: 1 program whose next study reaches primary completion

  1. elranatamabphase 2 · May 31 · NCT06988488

Bristol-Myers Squibb, Jun ’27: 3 programs whose next study reaches primary completion

  1. BMS-986533phase 1 · Jun 1 · NCT07629999
  2. BMS-986485phase 1 · Jun 8 · NCT07887763
  3. BMS-986454phase 1 · Jun 28 · NCT07171983

Bristol-Myers Squibb, Jul ’27: 1 program whose next study reaches primary completion

  1. zolacabtagene autoleucelphase 3 · Jul 15 · NCT06220201

Bristol-Myers Squibb, Aug ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. atigotatugphase 3 · Aug 17 · NCT06646276

Bristol-Myers Squibb, Sep ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. dezandrodegphase 3 · Sep 12 · NCT06764485

Bristol-Myers Squibb, Oct ’27: 1 program whose next study reaches primary completion

  1. BMS-986488phase 1 · Oct 15 · NCT06764771
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 22, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Boehringer Ingelheim

New programs 3

  • BI 4015092phase 1 · first study · Nov 3
  • BI 3968621phase 1 · first study · Sep 25
  • pumitamigphase 2 · first study · Sep 22 · Carcinoma, Non-Small-Cell Lung

Reached a new phase 1

  • BI 3810477phase 2 · Nov 3 · Idiopathic Pulmonary Fibrosis

Study stopped 0

None

Primary completion later 7

AstraZeneca

New programs 2

Reached a new phase 1

Study stopped 0

None

Primary completion later 23

Bristol-Myers Squibb

New programs 5

  • BMS-986548phase 2 · first study · Nov 10
  • BMS-986485phase 1 · first study · Oct 14
  • BMS-986553phase 1 · first study · Oct 8 · Lupus Nephritis
  • RYZ711phase 2 · first study · Oct 1 · Prostatic Neoplasms
  • BMS-986527phase 1 · first study · Sep 22 · Carcinoma, Renal Cell

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Where they overlap

Conditions where at least two of them have programs: 52 in all, the first 12 here. A program counts in each condition its studies name most.

ConditionBoehringer IngelheimAstraZenecaBristol-Myers Squibb
Carcinoma, Non-Small-Cell Lungall three · compare here

Boehringer Ingelheim in Carcinoma, Non-Small-Cell Lung: 4 programs

  1. zongertinibphase 3
  2. ezabenlimabphase 3
  3. Etoposidephase 3
  4. pumitamigphase 2

Their studies: Boehringer Ingelheim’s studies of Carcinoma, Non-Small-Cell Lung in search

AstraZeneca in Carcinoma, Non-Small-Cell Lung: 16 programs

  1. rilvegostomigphase 3
  2. datopotamab deruxtecanphase 3
  3. tremelimumabphase 3
  4. volrustomigphase 3
  5. ceralasertibphase 3

and 11 more — sign in to see them all

Their studies: AstraZeneca’s studies of Carcinoma, Non-Small-Cell Lung in search

Bristol-Myers Squibb in Carcinoma, Non-Small-Cell Lung: 11 programs

  1. navlimetostatphase 3
  2. pumitamigphase 3
  3. adagrasibphase 3
  4. izalontamab brengitecanphase 3
  5. repotrectinibphase 3

and 6 more — sign in to see them all

Their studies: Bristol-Myers Squibb’s studies of Carcinoma, Non-Small-Cell Lung in search

Breast Neoplasmsall three · compare here

Boehringer Ingelheim in Breast Neoplasms: 2 programs

  1. zongertinibphase 3
  2. pumitamigphase 2

Their studies: Boehringer Ingelheim’s studies of Breast Neoplasms in search

AstraZeneca in Breast Neoplasms: 10 programs

  1. datopotamab deruxtecanphase 3
  2. saruparibphase 3
  3. capivasertibphase 3
  4. camizestrantphase 3
  5. puxitatug samrotecanphase 3

and 5 more — sign in to see them all

Their studies: AstraZeneca’s studies of Breast Neoplasms in search

Bristol-Myers Squibb in Breast Neoplasms: 4 programs

  1. pumitamigphase 3
  2. izalontamab brengitecanphase 3
  3. actinium AC-225 dotatatephase 3
  4. Cyclophosphamidephase 2

Their studies: Bristol-Myers Squibb’s studies of Breast Neoplasms in search

Neoplasmsall three · compare here

Boehringer Ingelheim in Neoplasms: 1 program

  1. ezabenlimabphase 3

Their studies: Boehringer Ingelheim’s studies of Neoplasms in search

AstraZeneca in Neoplasms: 6 programs

  1. saruparibphase 3
  2. ceralasertibphase 3
  3. Leucovorinphase 2
  4. Ramucirumabphase 2
  5. AZD1390phase 1

and 1 more — sign in to see them all

Their studies: AstraZeneca’s studies of Neoplasms in search

Bristol-Myers Squibb in Neoplasms: 5 programs

  1. repotrectinibphase 3
  2. BMS-986488phase 1
  3. BMS-986500phase 1
  4. Digoxinphase 1
  5. relatlimabapproved, new study

Their studies: Bristol-Myers Squibb’s studies of Neoplasms in search

Small Cell Lung Carcinomaall three · compare here

Boehringer Ingelheim in Small Cell Lung Carcinoma: 5 programs

  1. obrixtamigphase 3
  2. ezabenlimabphase 3
  3. Etoposidephase 3
  4. pumitamigphase 2
  5. Zocilurtatug Pelitecanphase 2

Their studies: Boehringer Ingelheim’s studies of Small Cell Lung Carcinoma in search

AstraZeneca in Small Cell Lung Carcinoma: 2 programs

  1. tremelimumabphase 3
  2. durvalumabapproved, new study

Their studies: AstraZeneca’s studies of Small Cell Lung Carcinoma in search

Bristol-Myers Squibb in Small Cell Lung Carcinoma: 5 programs

  1. pumitamigphase 3
  2. izalontamab brengitecanphase 3
  3. atigotatugphase 3
  4. BMS-986525phase 2
  5. atigotatugphase 2

Their studies: Bristol-Myers Squibb’s studies of Small Cell Lung Carcinoma in search

Carcinoma, Hepatocellularall three · compare here

Boehringer Ingelheim in Carcinoma, Hepatocellular: 1 program

  1. pumitamigphase 2

Their studies: Boehringer Ingelheim’s studies of Carcinoma, Hepatocellular in search

AstraZeneca in Carcinoma, Hepatocellular: 6 programs

  1. rilvegostomigphase 3
  2. tremelimumabphase 3
  3. Leucovorinphase 2
  4. Anti-GPC3 T Cell-engaging Antibody AZD9793phase 2
  5. Ramucirumabphase 2

and 1 more — sign in to see them all

Their studies: AstraZeneca’s studies of Carcinoma, Hepatocellular in search

Bristol-Myers Squibb in Carcinoma, Hepatocellular: 4 programs

  1. pumitamigphase 3
  2. Actinium Ac 225 GPC3-targeted Peptide RYZ801phase 2
  3. Nivolumabapproved, new study
  4. relatlimabapproved, new study

Their studies: Bristol-Myers Squibb’s studies of Carcinoma, Hepatocellular in search

Pulmonary Disease, Chronic Obstructiveall three · compare here

Boehringer Ingelheim in Pulmonary Disease, Chronic Obstructive: 1 program

  1. verducatibphase 3

Their studies: Boehringer Ingelheim’s studies of Pulmonary Disease, Chronic Obstructive in search

AstraZeneca in Pulmonary Disease, Chronic Obstructive: 8 programs

  1. tozorakimabphase 3
  2. GP MDIphase 3
  3. AZD6793phase 2
  4. Treatment A: BGF MDI HFOphase 1
  5. tezepelumabapproved, new study

and 3 more — sign in to see them all

Their studies: AstraZeneca’s studies of Pulmonary Disease, Chronic Obstructive in search

Bristol-Myers Squibb in Pulmonary Disease, Chronic Obstructive: 1 program

  1. trospium chlorideapproved, new study

Their studies: Bristol-Myers Squibb’s studies of Pulmonary Disease, Chronic Obstructive in search

Heart Failureall three · compare here

Boehringer Ingelheim in Heart Failure: 2 programs

  1. vicadrostatphase 3
  2. empagliflozinapproved, new study

Their studies: Boehringer Ingelheim’s studies of Heart Failure in search

AstraZeneca in Heart Failure: 6 programs

  1. elecoglipronphase 3
  2. baxdrostatphase 3
  3. balcinrenonephase 3
  4. Pexerelgonphase 2
  5. dapagliflozinapproved, new study

and 1 more — sign in to see them all

Their studies: AstraZeneca’s studies of Heart Failure in search

Bristol-Myers Squibb in Heart Failure: 1 program

  1. delocamtenphase 2

Their studies: Bristol-Myers Squibb’s studies of Heart Failure in search

Colorectal Neoplasmsall three · compare here

Boehringer Ingelheim in Colorectal Neoplasms: 3 programs

  1. ezabenlimabphase 3
  2. pumitamigphase 2
  3. Anti-B7-H6/Anti-CD3 Bispecific Antibody BI 765049phase 1

Their studies: Boehringer Ingelheim’s studies of Colorectal Neoplasms in search

AstraZeneca in Colorectal Neoplasms: 1 program

  1. Leucovorinphase 2

Their studies: AstraZeneca’s studies of Colorectal Neoplasms in search

Bristol-Myers Squibb in Colorectal Neoplasms: 3 programs

  1. pumitamigphase 3
  2. adagrasibphase 3
  3. Nivolumabapproved, new study

Their studies: Bristol-Myers Squibb’s studies of Colorectal Neoplasms in search

Lupus Erythematosus, Systemicall three · compare here

Boehringer Ingelheim in Lupus Erythematosus, Systemic: 1 program

  1. BI 3000202phase 2

Their studies: Boehringer Ingelheim’s studies of Lupus Erythematosus, Systemic in search

Bristol-Myers Squibb in Lupus Erythematosus, Systemic: 3 programs

  1. zolacabtagene autoleucelphase 3
  2. obexelimabphase 3
  3. deucravacitinibapproved, new study

Their studies: Bristol-Myers Squibb’s studies of Lupus Erythematosus, Systemic in search

Obesityall three · compare here

Boehringer Ingelheim in Obesity: 2 programs

  1. survodutidephase 3
  2. BI 3034701phase 2

Their studies: Boehringer Ingelheim’s studies of Obesity in search

AstraZeneca in Obesity: 4 programs

  1. elecoglipronphase 3
  2. lenbelintidephase 3
  3. AZD9550phase 2
  4. AZD1043phase 1

Their studies: AstraZeneca’s studies of Obesity in search

Bristol-Myers Squibb in Obesity: 1 program

  1. Digoxinphase 1

Their studies: Bristol-Myers Squibb’s studies of Obesity in search

Idiopathic Pulmonary Fibrosisall three · compare here

Boehringer Ingelheim in Idiopathic Pulmonary Fibrosis: 4 programs

  1. nerandomilastphase 3
  2. BI 3810477phase 2
  3. BI 765423phase 2
  4. BI 1819479phase 2

Their studies: Boehringer Ingelheim’s studies of Idiopathic Pulmonary Fibrosis in search

AstraZeneca in Idiopathic Pulmonary Fibrosis: 1 program

  1. AZD8965phase 2

Their studies: AstraZeneca’s studies of Idiopathic Pulmonary Fibrosis in search

Bristol-Myers Squibb in Idiopathic Pulmonary Fibrosis: 1 program

  1. admilparantphase 3

Their studies: Bristol-Myers Squibb’s studies of Idiopathic Pulmonary Fibrosis in search

Melanomaall three · compare here

Boehringer Ingelheim in Melanoma: 1 program

  1. BI 3810944phase 1

Their studies: Boehringer Ingelheim’s studies of Melanoma in search

AstraZeneca in Melanoma: 3 programs

  1. tremelimumabphase 3
  2. ceralasertibphase 3
  3. CD8-guided IL-2 Fusion Protein AZD6750phase 2

Their studies: AstraZeneca’s studies of Melanoma in search

Bristol-Myers Squibb in Melanoma: 2 programs

  1. Nivolumabapproved, new study
  2. relatlimabapproved, new study

Their studies: Bristol-Myers Squibb’s studies of Melanoma in search

Show all 52

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

A target, or a pathogen for a vaccine, known for: Boehringer Ingelheim 24 of 45 · AstraZeneca 68 of 119 · Bristol-Myers Squibb 32 of 57 programs (53 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (Boehringer Ingelheim: 21, AstraZeneca: 5, Bristol-Myers Squibb: 9).